Freenome Stock

Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome

About Freenome Stock

Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.

Funding History

June 2016	$5.5M
March 2017	$65.0M
August 2017	$7.0M

Management

Co-Founder, COO

Riley Ennis

Data Scientist

Kate Niehaus

Co-Founder, CTO

Michael Otte

Chief Bioinformatician

Adam Drake

CEO, Co-Founder

Gabriel Otte

Press

These South Bay and Peninsula cities are raking in venture capital

TechCrunch - Jul, 8 2017

Other Companies

Learn More

Baxter International

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people.

Multinational pharmaceutical and life sciences company

Evolve BioSystems is developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome.

Steep Hill Labs opened the first commercial cannabis lab in the United States in 2007.

12Age (years)

$6.3MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Freenome or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 110K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2020 EquityZen Inc. All rights reserved.